CV, June, l995, UWSOM standards



March 2009

Margaret Rosenfeld, M.D., M.P.H.

Curriculum Vitae

PERSONAL DATA:

Born: 2/2/61, Berkeley, CA

Married: Daniel S. Weld

Children: Adam, Galen and Leah Weld

CONTACT INFORMATION:

Division of Pulmonary Medicine, A5937

Seattle Children’s Hospital

4800 Sandpoint Way NE, Seattle, WA 98105

(206) 987-5644

mrosen@u.washington.edu

EDUCATION

l983 B.S., Molecular Biophysics and Biochemistry, Yale University,

New Haven, CT. Magna cum laude, Distinction in the Major

l988 M.D., Harvard Medical School, Boston, MA

1995 M.P.H., Department of Epidemiology, University of Washington

School of Public Health, Seattle, WA

POSTGRADUATE TRAINING

l988-91 Internship/Residency in Pediatrics, University of Washington School of Medicine/Children's Hospital and Medical Center, Seattle, WA

l992-95 Fellowship, Pediatric Pulmonology, University of Washington

School of Medicine, Seattle, WA

FACULTY POSITIONS HELD

1995-1998 Acting Instructor, Department of Pediatrics, University of

Washington School of Medicine, Seattle, WA

2000. Acting Assistant Professor, Department of Pediatrics, University of

Washington School of Medicine, Seattle, WA

2000-2005 Assistant Professor, Department of Pediatrics, University of

Washington School of Medicine, Seattle, WA

2005- Associate Professor, Department of Pediatrics, University of

Washington School of Medicine, Seattle, WA

HOSPITAL POSITIONS HELD

1995- Attending Physician, Children’s Hospital and Regional Medical Center

2000- Medical Director, Pulmonary Function Laboratory, CHRMC

2003- Co-Director, Fellows’ College

2007- Medical Director, Pediatric Clinical Research Center, and Associate Director, Center for Clinical and Translational Research, Seattle Children’s Hospital Research Institute

HONORS

1992-98 Leroy Matthews Physician Scientist Award, Cystic Fibrosis Foundation

1993 Physician Scientist Fellowship Award, Glaxo Corporation

BOARD CERTIFICATION

l993, 2000 Diplomate, General Pediatrics, American Board of Pediatrics (expired as of 1/31/2006)

1998, 2005 Diplomate, Pediatric Pulmonology, American Board of Pediatrics

LICENSURE

l988- State of Washington, # 00027801

PROFESSIONAL ORGANIZATIONS

American Academy of Pediatrics

American Thoracic Society

Society for Pediatric Research

Western Society for Pediatric Research

Association for Patient Oriented Research

Association of Pediatric Program Directors

TEACHING RESPONSIBILITIES

Courses:

1991- Housestaff noon conference didactic sessions on chronic cough, obstructive sleep apnea, and common airway disorders (each given annually)

1992- Visiting lecturer, NURS 517 (Pediatric Nurse Practitioner graduate course), University of Washington School of Nursing (annually)

1995- Attending rounds didactic sessions to resident ward team on various relevant topics in pediatric pulmonary medicine (cystic fibrosis, pulmonary physiology, asthma, bronchiolitis)

1995-2002 Visiting lecturer, Core Pediatrics Clerkship,

University of Washington School of Medicine (~ 6 times annually)

2002- 2007 Lecturer, Core Pediatrics Clerkship, ethics session (9 times annually)

2004- Lecturer, HuBio 512 course to 1st year medical students (lectures on cystic fibrosis)

2007 Lecturer and panel discussant, UW Educational Outreach 88597-Intro to Clinical Trials

Trainees:

1999. Graduate thesis preceptor for Toby Lewis, M.D., M.P.H., former fellow, Division of Pulmonary Medicine. Advised her in design, conduct and analysis of her study assessing outcomes associated with urban vs. rural residence among cystic fibrosis patients in the U.S. CF Foundation National Registry. Dr. Lewis is currently an Assistant Professor in the Division of Pulmonary Medicine, Department of Pediatrics, University of Michigan School of Medicine.

1999. Research mentor for Victoria Cartwright, MD, former fellow in Division of Rheumatology, “A Randomized, Controlled Trial of Pain Management Methods for Intraarticular Steriod Injections in Patients with Juvenile Rheumatoid Arthritis.” Dr. Cartwright is currently on faculty in the Department of Pediatrics at Madigan Army Medical Center in Tacoma, WA.

2001 Research mentor to Chris Goss, MD, MSc, now Assistant Professor, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington School of Medicine. Assisted him in preparation of his successful grant applications to the Cystic Fibrosis Foundation for a LeRoy Matthews Physician Scientist Award and to the NIH for a K23 award. His proposals assess the quality of life in cystic fibrosis patients with end-stage lung disease.

2001- Research mentor to Jason Debley, MD, Assistant Professor, Division of Pulmonary Medicine. Assisted him in preparing three successful grant applications and currently serve as one of his mentors on his NIH K23 career development award assessing predictors of asthma among wheezy infants utilizing infant pulmonary function tests.

2002- 2004 Advisor to Doris Uh, Pharm.D., postdoctoral fellow, Department of Pharmaceutics. Mentored her in investigation of pharmacokinetics of inhaled antibiotics and supervising her role as consulting clinical pharmacist in the Division of Pediatric Pulmonary Medicine.

2003 Research mentor to Martha McKinney, MD, MPH, former fellow, Division of Pulmonary Medicine. Assisted her in her preparing her thesis in fulfillment of the Masters in Public Health degree, assessing the prevalence of smoking among Canadian asthmatics. Sat on her thesis committee. Dr. McKinney is currently an Assistant Professor, Department of Paediatrics, Queen's University, Kingston, Ontario.

2006- Research Mentor to Maida Chen, Acting Assistant Professor, Division of Pulmonary Medicine, on her submitted grant application to University of Washington. Alcohol and Drug Abuse Institute, ”Sleep in Fetal Alcohol Spectrum Disorders,” and for her planned application for an NIH K12 career development award, “Sleep Disordered Breathing in Special Needs Pediatric Populations.”

2007-08 Biology project advisor to Paramita Saha, doctoral candidate in Biostatistics

2007- Member, Scholarship Oversight Committee of Don “DB” Sanders, fellow in Pulmonary Medicine

2008- Primary Mentor to Maida Chen, MD, Assistant Professor of Pediatrics, Division of Pulmonary Medicine, through Seattle Children’s Hospital Research Institute Center for Clinical and Translational Research Mentored Scholar Program

EDITORIAL RESPONSIBILITIES

Regular reviewer for American Journal of Respiratory and Critical Care Medicine, Pediatric Pulmonology, Journal of Pediatrics, Annals of Epidemiology, Thorax, European Respiratory Journal, Pediatric Infectious Diseases, Journal of Antimicrobial Chemotherapy, Journal of Cystic Fibrosis, Chest, JAMA

2006 Guest Editor, Proceedings of the American Thoracic Society, “Imaging Endpoints in Cystic Fibrosis”

SPECIAL NATIONAL RESPONSIBILITIES

2000. Participant in development of Pulmonology subspecialty examination, American Board of Pediatrics

1999. Correspondent Reviewer, NIDDKM K01 grant application

2002-2003 Member, Nominating Committee, Pediatric Assembly, American Thoracic Society

2002-2004 Member, American Thoracic Society Health Care Policy Committee

2002-2004 Member, Cystic Fibrosis Foundation Therapeutics Development Network Protocol Review Committee

2003 Manuscript judge, 2003 Uniformed Services Scientific Award Competition

2004. Member, Writing Committee, “The Clinical Utility of Newborn Screening for Cystic Fibrosis” report published in Morbidity and Mortality Weekly Reports in 2004

2003-2007 Member, American Thoracic Society Pediatric Assembly Planning Committee

2005-2006 Chair, U.S. Cystic Fibrosis Foundation task force On Updating Spirometry Reference Equations for the CFF National Patient Registry

2005-2007 Member, American Thoracic Society Pediatric Assembly Program Committee

2006 Co-Chair, U.S. Cystic Fibrosis Foundation workshop on Defining a Pulmonary Exacerbation, held Sept 17-18, 2006, Bethesda, MD

2007 Faculty Member, Cystic Fibrosis Foundation Learning and Leadership Collaborative V

2003- Member, Cystic Fibrosis Foundation National Patient Registry Committee

2004- Member, Cystic Fibrosis Foundation Therapeutics Development Network Publication and Presentations Committee

2005- Vice-Chair, EPIC (Early Pseudomonas Infection Control) Steering Committee

2007- Co-Chair, Cystic Fibrosis Foundation Therapeutics Development Network Working Group on Outcome Measures in Young Children with CF

2008- Chair, American Thoracic Society Working Group on Infant / Preschool Lung Function

2008- WA State representative to the Cystic Fibrosis Foundation Special Interest Group on CF Newborn Screening

SPECIAL LOCAL RESPONSIBILITIES

1997-2000 Subspecialty Teaching Ad Hoc Subcommittee of the Residency Committee, Children’s Hospital and Regional Medical Center

1997- Residency Program Liaison, Division of Pulmonary Medicine, Children’s Hospital and Regional Medical Center

2002, 2005 Reviewer, Cystic Fibrosis Critical Elements of Care Community Provider Guidelines, Center for Children with Special Needs and Chronic Health Conditions, CHRMC

1998- Member, Scientific Advisory Committee to the Clinical Research Center, UW and CHRMC.

2000-2003 Member, UW Clinical Research Training Grant K-30 Steering Committee – Training Grant Program Track

2001-2002 Member, Newborn Screening Advisory Committee to Washington State Board of Health regarding additional universal newborn screening tests.

2001- Member, CHRMC Pharmacy and Therapeutics Committee

2000- Member, Medical Advisory Board, World Bike for Breath

2003- Member, Faculty Council on Academic Affairs, UW School of Medicine

2004- Member, Education Committee, University of Washington School of Medicine General Clinical Research Center

2005-2006 Member, Institutional Resident/Fellow Advisory Committee (IR/FAC), University of Washington School of Medicine

2006 Member, CHRMC Strategic Plan Task Force on Education

2006 Leader, Workgroup on Family Support Services for Symposium on Creating Institutional Change for Work-Life Balance in Pediatric Careers, CHRMC, October 11, 2006

2007 Member, Seattle Children’s Hospital Research Institute Center for Health Services and Behavioral Research Strategic Planning Committee

2007 Member, Seattle Children’s Hospital Research Institute Center for Clinical and Translational Research Strategic Planning Committee

2007- Member, University of Washington Department of Pediatrics Recognition Committee

2007- Member, Steering Committee, Seattle Children’s Hospital Research Institute Center for Clinical and Translational Research

2008- Member, Leadership Committee, Institute for Translational Health Sciences (ITHS)

RESEARCH FUNDING

ACTIVE

OBSERV04K0 (Rosenfeld – PI) 4/1/04 – 3/31/09

3.0 calendar mo.

Cystic Fibrosis Foundation $384,782

EPIC Observational Study

A large, multicenter, prospective, descriptive study of the risk factors for and outcomes associated with initial acquisition of Pseudomonas aeruginosa as well as outcomes associated with therapy among CF patients 1 to 12 years of age. No overlap.

1 U54 FF019480 (Knowles – PI) 8/4/04 – 7/31/09

.60 calendar mo.

NIH (NCRR) (Subcontract from University of $382,893

North Carolina at Chapel Hill) (Rosenfeld – Site PI)

Genetic Disorders of Mucociliary Clearance

Four-center prospective, longitudinal study to define the onset and progression of lung disease in a cohort of patients with primary ciliary dyskinesia (PCD) using standardized procedures. No overlap.

UL1RR025014-01 (Disis – PI) 6/1/08 – 5/31/09

2.4 calendar mo.

University of Washington (UW), Institute of $1,560,594

Translational Health Science

Institutional Clinical and Translational Health Science Award CTSA

Dr. Rosenfeld is the Medical Director of the Pediatric Clinical Research Center, overseeing programs and infrastructure to conduct clinical research in the Pediatric Clinical Research Center located at Seattle Children’s Hospital. No overlap.

ISIS07K1 (Rosenfeld – PI) 10/1/07 – 9/30/12

0.0 calendar mo.

Cystic Fibrosis Foundation $350,639

Infant Study of Inhaled Saline

A large multicenter randomized controlled trial of inhale 7% hypertonic saline in infants with cystic fibrosis. This is a jointly funded project with NIH U01 092931.

U01 HL 092931 (Rosenfeld – PI) 9/15/08 – 7/31/12

2.4 calendar mo.

NIH/NHLBI $405,335

Infant Study of Inhaled Saline

A large multicenter randomized controlled trial of inhale 7% hypertonic saline in infants with cystic fibrosis. This is a jointly funded project with CFF ISIS07K0.

CFF EPIC09K0 (Rosenfeld – PI) 4/1/09 – 3/31/12

2.4 calendar mo.

Cystic Fibrosis Foundation Therapeutics Inc $764,187

EPIC Observational Study

The objectives of this study are to prospectively assess the risk factors for early age at acquisition of Pseudomonas aeruginosa (Pa) and clinical outcomes associated with Pa acquisition, in order to determine improved early prevention and treatment strategies.

ITHS Pilot Project 4/1/09-3/31/10

0 calendar mo

Institute for Translational Health Sciences $10,000

Parent Report of Respiratory and Gastrointestinal Signs in Infants and Young Children with Cystic Fibrosis: A Feasibility Study

Pilot study to develop a patient-centered outcome measure for clinical trials in young children with CF.

OVERLAP: CFF ISIS07K0 and NIH U01 HL092931 jointly fund the same project. Dr. Rosenfeld’s effort for the entire project is paid under NIH U01 HL092931.

PENDING:

(Knowles – PI) 8/1/09-7/31/14

.6 Calendar mo.

NIH (NCRR) (Subcontract from University of $129,739

North Carolina at Chapel Hill) (Rosenfeld – Site PI)

Genetic Disorders of Mucociliary Clearance

Multicenter prospective, longitudinal study to define the onset and progression of lung disease in a cohort of patients with primary ciliary dyskinesia (PCD) using standardized procedures.

Role: Site PI

Completed

1. K23 RR15529 (PI, Margaret Rosenfeld). Source: NCRR, NIH. Dates: 5/01/2000– 11/30/2005. Annual Direct Costs: $96,333. Percent Effort: 75%. Title: Mentored Patient Oriented Research Career Development Award

2. HR 597004 (PI: Margaret Rosenfeld). Source: Research Endowment Fund, Childrens Hospital and Regional Medical Center. Dates: 1/01/2002– 3/31/2004. Annual Direct Costs: $24,780. Percent Effort: 0%. Title: A pilot study of sputum induction as a non-invasive means to measure serial airway antibiotic concentration in cystic fibrosis.

3. Cystic Fibrosis Foundation, Leroy Matthew Physician Scientist Award (Bonnie Ramsey, MD PI, 1992-95 for my fellowship funding; M. Rosenfeld, PI, 1996-98). Dates: 1992-1998. 1997-98 direct costs: $65,250.

4. Pari Respiratory Equipment, for Study of Efficacy of Cleaning Methods for Small-Volume Nebulizers (M. Rosenfeld, PI). Date: 1997. Direct costs: $1,847.

5. PathoGenesis Corp., Safety Study of Aerosolized Tobramycin in Young Children with Cystic Fibrosis (M. Rosenfeld, PI). Dates: 4/98 – 10/98. Total direct costs: $90,591.

6. PathoGenesis Corp. and Cystic Fibrosis Foundation. A Pilot Study of the Deposition of Inhaled Tobramycin in Young Children with Cystic Fibrosis (M. Rosenfeld, PI). Dates: 4/99-5/00. Total award: $81,968.

7. ROSENF03AO (Rosenfeld – PI). Dates: 2/1/03 – 1/31/08. Funding source: Cystic Fibrosis Foundation Therapeutics, Inc. Direct Costs: $910,024. Title: Evaluation of pulmonary function from raised lung volumes as outcome measures for clinical trails in infants with cystic fibrosis.

8. ISIS07K1P (Rosenfeld – PI). Dates: 10/1/107 – 9/30/08. Source: Cystic Fibrosis Foundation Therapeutics, Inc. Direct costs:$112,745. Title: A Pilot Study to Evaluate Inhaled 7% Hypertonic Saline in CF Infants

BIBLIOGRAPHY

Manuscripts in Refereed Journals

1. Rosenfeld M, Ramsey B. Evolution of airway microbiology in the infant with cystic fibrosis: role of pseudomonal and non-pseudomonal pathogens. Semin Respir Infect 1992;7(3):158-67.

2. Rosenfeld M, Cohen M, Ramsey B. Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy and pitfalls. Clinical Pulmonary Medicine 1997;4(2):101-12. (Also appeared in Infectious Diseases in Clinical Practice 1998:7;66-79)

3. Rosenfeld M, Davis R, Fitzsimmons S, Pepe M, Ramsey B. The gender gap in cystic fibrosis mortality. American Journal of Epidemiology 1997;145(9):794-803.

4. Rosenfeld M, Emerson J, Astley S, Joy P, Williams-Warren J, Standaert T, Yim DL, Crist D, Thykkuttathil J, Torrence M, FitzSimmons S, Ramsey B. Home nebulizer usage among patients with cystic fibrosis. Journal of Pediatrics 1998;132:125-31.

5. Rosenfeld M, Casey S, Pepe M, Ramsey B. Nutritional effects of long term gastrostomy feedings in children with cystic fibrosis. Journal of the American Dietetic Association 1999;99:191-4.

6. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, Wagener J. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatric Pulmonology, 1999;28:321-328.

7. Rosenfeld M, Pepe MS, Emerson J, Longton G, FitzSimmons S. Effect of different reference equations on the analysis of pulmonary function data in cystic fibrosis. Pediatric Pulmonology 2001;31:227-37.

8. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey BW. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Disease 2001;183(3):444-452.

9. Rosenfeld M, Emerson J, Willians-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey BW. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139(3):359-365.

10. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, Smith A, Martin TR, Ramsey BW. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology 2001;32:356-366.

11. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoy K, Shell R, Borowitz D, Konstan M, Retsch-Bogart G, Wilmott RW, Burns JL, Vicini P, Montgomery B, Ramsey B. Serum and lower respiratory tract drug concentrations produced by tobramycin for inhalation in young children with cystic fibrosis. Journal of Pediatrics 2001;139(4):572-7.

12. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas and other predictors of mortality and morbidity among young children with cystic fibrosis. Pediatric Pulmonology 2002;34(2):91-100.

13. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. American Journal of Respiratory and Critical Care Medicine 2002;166:1550-5.

14. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Ramsey B. Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;167: 841-9.

15. Geller DW, Rosenfeld M, Waltz D, Wilmott R. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003; 123:28-36

16. Kulich M., Rosenfeld M., Goss CH, and Wilmott R.. Improved survival among young patients with cystic fibrosis. Journal of Pediatrics 2003:142(6);631-636.

17. Rosenfeld M, Gibson R, Ramsey BW. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Current Opinions in Pulmonary Medicine 2003;9(6):492-7.

18. Goss C, Rosenfeld M. Update on CF Epidemiology. Curr Opin Pulm Med 2004;10(6):510-4

19. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR 2004;53 (No. RR-13):1-35. Prepared by Grosse DS, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS.

20. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from U.S. observational studies. J Pediatr 2005;147(3 Suppl):S11-14.

21. Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ. The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study. J Pediatrics 2005 Aug;147(2):233-8.

22. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson R, Goss CH, Ramsey BW. Disease-specific reference equations for lung function among patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172(7): 885-91.

23. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006;148(2):259-64.

24. Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 2006;149:362-6.

25. Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, Parad RB, Wilfond BW, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O’Sullivan B. Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs. Pediatrics 2006: 112:e495-e518.

26. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Eradication of initial Pseudomonas aeruginosa infection in children with Cystic Fibrosis – What is the optimal treatment approach? Pediatric Pulmonology 2007;42(9): 751-6.

27. Rosenfeld M. Endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc. 2007 Aug 1;4(4):299-301

28. Davis SD, Brody A, Emond M, Rosenfeld M. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc. 2007 Aug 1;4(4):418-30.

29. Veenstra DL, Julie H, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: Potential impact on clinical, patient, and economic outcomes. Genetics in Medicine 2007; 9:695-704.

30. Sanders DB, Rosenfeld M, Mayer-Hamblett N, Stamey D, Redding GJ. Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations. Pediatr Pulmonol 2008; 43(11):1142-6.

31. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW, Inhaled tobramycin in young children study group, cystic fibrosis foundation therapeutics development network. Impact of pseudomonas and staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154(2):183-8.

32. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009; In Press.

Book Chapters

1. Marshall S, Rosenfeld M, Ramsey B. Respiratory System: Pediatrics. In Cystic Fibrosis, Hodson ME, Geddes DM, eds. Chapman and Hall Medical, London, 2000, pp. 204-218.

2. Davis S, Gappa M, Rosenfeld M. Respiratory Mechanics. In Pediatric Pulmonary Function Testing, Hammer J, Eber E, eds. Prog Respir Res, Kargar, Basel, 2005, vol 33, pp 20-33.

3. Tiddens H, Rosenfeld M. Cystic Fibrosis: Respiratory Manifestations. In Pediatric Respiratory Diseases. Taussig L editor. 2007 (in press).

4. Rosenfeld M. “Cystic Fibrosis” and “Bronchiectasis.” In: The Netter Collection of Medical Issustrations, 2nd Edition: The Respiratory System.” David Kaminsky, editor. Elsevier. 2009 (in press).

5. Sanders DB and Rosenfeld M. “Pulmonary Exacerbations.” In “Cystic Fibrosis.” Eds Julian Allen, Ronald Rubenstein, and Howard Panitch. Informa. 2009 (in press).

Other Publications

1. Rosenfeld, M. The gender gap in cystic fibrosis mortality. Thesis submitted in partial fulfillment of the Masters in Public Health degree, University of Washington, Seattle, WA, August, 1995.

2. Rosenfeld M, Joy P, Nguyen CD, Burns J. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough? Journal of Hospital Infection 2001;49(3):229-30.

Manuscripts Submitted

1. Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Huttierrez H, Kanga J, Lahiri T, Noyes B, Ramsey BW, Ren CL, Schechter M, Wagener J, Morgan W, Gibson R, for the EPIC Study Group. The Early Pseudomonas Infection Control (EPIC) Observational Study: Baseline characteristics and associations in a young cohort of children with cystic fibrosis. J Pediatrics 2009 (submitted)

2. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH. Return of FEV1 after Pulmonary Exacerbation in Children with Cystic Fibrosis. Pediatr Pulmonol 2009 (submitted)

Abstracts (Within Last 5 Years)

1. Rosenfeld M, Borowitz D, Emerson J, Gibson R, McCoy K, McNamara S, Montgomery B, Ramsey B, Vicini P, Wilmott B. Safety and serum pharmacokinetics of inhaled tobramycin in very young CF patients. Pediatric Pulmonology 1999;S19,262.

2. Lewis TC, Rosenfeld M, Gibson R, Ramsey B. Urban/rural differences in specialty health care utilization and health outcomes in cystic fibrosis. Pediatric Pulmonology 1999;S19,367.

3. Vicini P, Rosenfeld M, Borowitz D, Emerson J, Gibson R, McCoy K, McNamara S, Montgomery B, Ramsey B, Wilmott B. Population pharmacokinetics of inhaled tobramycin in CF patients ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download